Clin2
NCT05924425Possibly a fitRecruiting

Daridorexant for insomnia in early memory decline

Alzheimer DiseaseInsomnia DisorderSleep

Treatments studied

Part of Brain & nervous system, Mental health clinical trials.

This trial tests whether daridorexant can improve sleep in people who have mild cognitive impairment or early Alzheimer’s disease and struggle with insomnia. It may help by improving how long and how well you sleep, with monitoring of sleep patterns and memory-related measures.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
62 people
Ages
60 years to 85 years
Study type
Interventional

Who can take part

  • Be between 60 and 85 years old
  • Live at home (outpatient), not in a facility, and be able to attend visits for at least 2 months
  • Have at least 3 months of poor sleep (at least 3 nights per week) that affects daytime life, with typical total sleep time under 6 hours
  • Agree to sleep testing at the start (PSG): total sleep time under 6 hours and being awake more than 1 hour during the night
  • Have early-stage diagnosis of mild cognitive impairment or mild to moderate Alzheimer’s disease and be able to do memory/neuropsych tests (MMSE 12–26, CDR 0.5–2)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06274528Recruiting· Phase 2
DORA and lemborexant in Alzheimer's biomarkers study

This study is testing whether a sleep medication called lemborexant can improve sleep and reduce Alzheimer's-related proteins in healthy older adults with no memory problems. It could help find new ways to delay or prevent Alzheimer's disease.

St Louis, Missouri
NCT04629547Recruiting· Phase 2
Sleep study to help prevent Alzheimer’s disease

This trial tests whether treating sleep issues and measuring sleep can help lower the risk of Alzheimer’s disease before it starts. It focuses on older adults with no dementia signs yet.

St Louis, Missouri
NCT07328594Not yet recruiting· Phase 4
Sleep medication to help smokers quit or cut back

This study tests whether a new sleep medication, daridorexant, can help smokers sleep better and feel more alert during the day, while also supporting their efforts to quit or reduce smoking. You will monitor your sleep at home, keep a diary, and take short mobile tests for 3 weeks.

Portland, Oregon
NCT07743931Not yet recruiting
Combined CPAP and medication for sleep apnea with insomnia

This study is testing a new approach for people who have both sleep apnea and insomnia, called 'COMISA'. It looks at whether using a CPAP machine together with a medication (daridorexant) helps improve their sleep better than standard care.

Marseille
NCT07213349Recruiting· Phase 2
Daridorexant for Alzheimer's prevention

This study tests whether daridorexant, a medication that helps improve sleep, can prevent Alzheimer's disease. If you have mild memory concerns but not dementia, this trial may help find out if better sleep can protect your brain.

Montreal, Quebec
NCT07701928Not yet recruiting· Phase 2
Daridorexant for sleep and alcohol use disorder

This trial tests if the sleep medication daridorexant can help people who have both insomnia and alcohol use disorder. It looks at whether the drug improves sleep and reduces drinking.

Spokane, Washington

Hear when a new Insomnia Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.